What Questions are Current Myeloma Trials NOT Answering | Invited Talk to UK Myeloma Research Day

[@dolphinmorbid]

Thank u man, totally agree, almost took 10 years as an hematologist to begin to understand this stuff (not the sharpest tool in the shed here) we are very manipulated, you are the only one i heard talking about this. But c'mon guys, dont be greedy, you selling your souls very cheap, listen to your patients, feel their pain a little bit or stay in the lab, no shame about it.

[@lindiasanders3948]

My Dad had this ♋ CANCER. A WW2 Hero U.S. Navy.

[@areugnat5484]

So sorry to hear that!

[@mrs.m4002]

This is a fascinating video even though I'm neither a doctor nor a scientist and didn't understand it all. I DID understand the policy point toward the end about disclosure vs. recusal and found it enlightening (particularly that regulators who comply with disclosure requirements feel licensed to engage in whatever conflict of interest is most lucrative to them, having followed the letter of the law). Disclosure is simply not a reasonable remedy for regulators! Regulators aren't elected and therefore what's the point of disclosing - to infuriate the public, who didn't vote for them, even more than they're already infuriated? Recusal is the typical remedy for judicial conflicts of interest and should be, as you indicate, required of appointed administrators as well. And if they don't recuse themselves, they should be recused, permanently.

[@neighborhoodwatch470]

The Whitehouse channel actually has the comment section open! Hit em up people!

[@kingdom8474]

Please upload to Rumble! I can listen to you with my phone locked and without ads!

[@jldefoa]

Are they considering the role of insulin & IGF in the context of increased growth-promoting short Type A insulin Receptors, which can hybridize with IGF-! Receptors, on many malignant cells, including Multiple Myeloma cells.

[@yunshiggy]

Great video. I disagree somewhat re: not treating based on SFLC ratio - 80% progression at 2 years is pretty high. Your point is well taken re: the 20% who don't need therapy, but seeing patients q 2-3 months with labs +/- imaging is stressful for patients AND when these patients do progress, they never progress when seen in clinic...they typically progress with an admssion requiring transfusion dependence, fractures, renal failure, and in some, a poor performance status that may preclude initiation of effective induction therapy

[@danieljohnson309]

VP, what do you think about this idea: When it comes to any/all Lymphomas, it sometimes looks like using one therapy after another actually drives the mutation process forward until the disease eventually becomes untreatable. Shouldn't we be studying cell lines and mutation selection processes - esp. among immune cell types such as Killer T's? Because in theory, if the immune system functioned properly, monoclonal lines would be recognized and destroyed naturally by the body's own immune sys, right? Just wondering about this. Cheers -

[@mballer]

None of the studies took into account all molecule (food) intake did they?